Clinical trials: Prevention of Herpes Zoster
Mumps, Varicella
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
- Conditions
- Mumps, Varicella, Rubella, Measles
- Trial name
- NCT00127023
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 85 sites in Germany
- Volunteers
- 944 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant…
- Trial name
- NCT04006808
- Testing
- PED-HZ/su
- Where
- 31 sites in Belgium, France and 4 more
- Volunteers
- 184 people
- Sponsor
- GlaxoSmithKline
Varicella
The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age
This study evaluates the immunogenicity and safety of three different potencies of NBP608 and Varivax which are indicated for active immunization for the prevention of varicella.
- Trial name
- NCT03114982
- Testing
- NBP608, Varivax
- Where
- Philippines
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Zoster Without Complications
Regional Anesthesia to Relief Zoster Pain
Pain in Herpes is a serious issue for patients. at the acute phase it is a moderate to severe pain . 30% patients will develop a post herpetic neuralgia this percentage up to 70 % after 60 years old.
- Trial name
- NCT04133142
- Testing
- peripheral nerve block, inter fascial nerve block
- Where
- Vietnam
- Sponsor
- Vinmec Healthcare System
Measles, Rubella
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
- Conditions
- Measles, Rubella, Mumps, Varicella
- Trial name
- NCT00127010
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 48 sites in Belgium, Germany and 1 more
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella Zoster Virus Infection, Herpes Simplex Virus Infection
Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir
A new paediatric formulation (oral liquid) has been developed for flexible and accurate dosing of valacyclovir in children. To establish the bioavailability of this new formulation, healthy volunteers will be exposed to the new…
- Trial name
- VALID-I (NCT01689285)
- Testing
- valacyclovir tablet, valacyclovir oral solution
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Herpes Zoster
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
The purpose of this study is to determine whether the investigational zoster vaccine has a comparable immune response (the body's ability to protect against disease) and safety profile when given concomitantly with another…
- Trial name
- NCT00231816
- Testing
- ZOSTAVAX™ (concomitant), Comparator: Influenza Vaccine, ZOSTAVAX™ (Nonconcomitant)
- Volunteers
- 763 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting
The purpose of this study is to determine whether pharmacist-driven patient interventions can have an effect on the number of herpes zoster (Zostavax) vaccinations given in a community pharmacy setting.
- Trial name
- NCT00689013
- Testing
- Personalized letter, Flyer advertisement, Newspaper press release
- Where
- 3 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- University of Tennessee
Prevention of Herpes Zoster
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine. To evaluate the safety of the live attenuated herpes zoster vaccine.
- Trial name
- NCT06961721
- Testing
- Herpes Zoster Vaccine, Live
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Herpes Zoster
Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
This study assesses non-inferiority by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax which are evaluated by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay).
- Trial name
- NCT03116594
- Testing
- NBP608, Zostavax
- Where
- South Korea
- Volunteers
- 675 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Herpes Zoster
Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia
All eligible Herpes Zoster patients will be randomized into two groups. Group 1 will be the treatment group receiving Pregabalin 75 mg twice daily for 4 weeks in addition to other routine treatment.
- Trial name
- NCT03809702
- Testing
- Pregabalin
- Where
- Nepal
- Volunteers
- 82 people
- Sponsor
- B.P. Koirala Institute of Health Sciences
Mumps, Rubella
Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
This is a study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals live attenuated measles-mumps-rubella-varicella vaccine given to healthy children in their second year of life.
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT00126997
- Testing
- Measles, Mumps, Rubella and Chickenpox (live vaccine)
- Where
- 54 sites in Finland, Germany and 2 more
- Volunteers
- 1,439 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Safety Study of ProQuad® rHA in Infants (V221-037)
Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00560755
- Testing
- ProQuad®
- Volunteers
- 3,388 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Prevention of Herpes Zoster (HZ)
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers
This is a Phase 1, first in human (FIH), randomised, active-controlled, double-blind study designed to assess the safety and tolerability and explore preliminary efficacy of the EG-HZ vaccine.
- Trial name
- NCT04210752
- Testing
- Treatment 1 (EG-HZ-001), Treatment 2 (EG-HZ-002), Treatment 3 (EG-HZ-003)
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- EyeGene Inc.
Postherpetic Neuralgia
Ultrasound-Guided Thoracic Paravertebral Block With Steroid and Local Anesthetic for Acute Herpes Zoster: Effects on Pain Control and Prevention of Postherpetic Neuralgia
Background: Acute herpes zoster causes severe neuropathic pain and may progress to postherpetic neuralgia (PHN). This study aims to evaluate ultrasound-guided thoracic paravertebral block with local anesthetic and steroid in…
- Trial name
- NCT07349680
- Testing
- Valacyclovir + Paracetamol (Acetaminophen) + Gabapentin (standard medical therapy), Ultrasound-guided thoracic paravertebral block (TPVB) with bupivacaine 0.25% + methylprednisolone 40 mg
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Cardiovascular Disease, Dementia
Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia
DAN-ZOSTER is a nationwide randomized study investigating whether vaccination against herpes zoster (shingles) can reduce the risk of cardiovascular disease and dementia in older adults.
- Trial name
- DAN-ZOSTER (NCT07485283)
- Testing
- Recombinant Herpes Zoster Vaccine (Shingrix)
- Where
- 2 sites in Denmark
- Volunteers
- 168,460 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Shingles, Herpes Zoster
A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
This is a multicenter, randomized, double-blind, parallel-group, active controlled comparative study of the safety and efficacy of 2 dosing regimens of FV-100 versus valacyclovir administered for 7 days in subjects with…
- Conditions
- Shingles, Herpes Zoster, Postherpetic Neuralgia
- Trial name
- NCT02412917
- Testing
- FV-100, valacyclovir
- Where
- United States
- Volunteers
- 237 people
- Sponsor
- ContraVir Pharmaceuticals, Inc.
Pain
Prevention of Post Herpetic Neuralgia by Ultrasound Guided Single Nerve Block in the ED
Herpes zoster causes significant morbidity on over 1 million Americans every year. Although the majority of herpes zoster pain will self-resolve within one week, a significant proportion of patients will develop postherpetic…
- Trial name
- NCT04530162
- Testing
- Ultrasound guided nerve block
- Where
- United States
- Sponsor
- Antonios Likourezos
Herpes Zoster, Postherpetic Neuralgia
Shingles Prevention Study
The incidence and severity of HZ (or shingles), as well as the frequency and severity of its complications, increases markedly with increasing age. More than half of all cases occur in persons over the age of 60.
- Trial name
- SPS (NCT00007501)
- Testing
- Varicella-zoster vaccine
- Where
- 22 sites in United States
- Volunteers
- 38,456 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Vaccine-Preventable Diseases, Herpes Zoster
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.
- Trial name
- NCT06137755
- Testing
- CVI-VZV-001, Shingrix
- Where
- 2 sites in South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Aribio Lab Co., Ltd.